Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant 2009 May;15(5):554-63 PMID: 19361747 PMCID: PMC3120935

Pubmed ID



We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort.

Author List

van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN


Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin
Brent R. Logan PhD Director, Professor in the Institute for Health and Equity department at Medical College of Wisconsin


2-s2.0-63749130619   27 Citations

MESH terms used to index this publication - Major topics in bold

Age Distribution
Child, Preschool
Follow-Up Studies
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Lymphoma, Non-Hodgkin
Middle Aged
Retrospective Studies
Risk Factors
Survival Analysis
Tissue Donors
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
Young Adult
jenkins-FCD Prod-299 9ef562391eceb2b8f95265c767fbba1ce5a52fd6